INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Alexion Pharmaceuticals, Inc. And Advises Investors With Losses To Contact The Firm

Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company") (Nasdaq: ALXN) concerning possible violations of federal securities laws.

If you purchased or otherwise acquired Alexion shares and would like more information regarding the investigation, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm's website at, or by email at

The investigation concerns whether Alexion and certain of its officers and/or directors violated federal securities laws. Alexion announced that is investigating accusations of improper sales practices of its top drug, Soliris, which is estimated to account for 92% of the Company's $3.1 billion in sales for 2016. The Company retained outside counsel and announced its decision to delay its third-quarter financial report. When this news was revealed, shares of Alexion fell in value.

If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at, or email us at

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

If you liked this article you might like

Alexion Could Target Sage, Ra Pharma: Analyst

Dow, S&P 500 and Nasdaq at New Records as Promise of Tax Reform Boosts Banks

Stocks Back at Highs as Apple Gains on iPhone 8, iPhone X Release

Tech in Wait-and-See Mode Ahead of Apple Event, Financials Rise on Tax Talk

Stocks Come Off Highs as Apple Wait Counters Boost From Tax Reform Talk